The present studies indicate that accumulation of pathogenic soluble tau aggregates in AD brain microvasculature is recapitulated in the P301S(PS19) mouse model of tauopathy and is associated with profound deficits in brain microvascular function that can be negated by removal of soluble tau aggregates with immunotherapy. The gene discussed is MAPT; the disease is Alzheimer disease.